AVIR
Atea Pharmaceuticals, Inc.
Recent 8-K filings for AVIR
Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.
-
May 12, 2026 20:17 UTC earnings item 2.02item 9.01
Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026
source · AVIR on sec.gov